We recently concluded the final two sessions of the TCS PIONEER Series on 5 November and 13 November, taking participants from patent fundamentals to global commercialization strategies.

In Session 3, Jennifer Che guided participants through different types of patent searches, including prior art/patentability searches and freedom-to-operate (FTO) searches, with practical exercises allowing participants to work through the search and analysis process themselves.

In Session 4, Pauli Wong took a case-study approach, using the “Price-Predict Pro” story to discuss with the audience what had gone wrong with the original PCT filing and, more importantly, what the best filing and broader IP strategy should be going forward. Participants considered different options, including whether to abandon and refile, amend and proceed, or adopt another strategy, before developing an overall recommendation.

Both sessions were highly interactive, combining practical exercises and case discussions to encourage participants to think through IP issues and make strategic decisions in real-world scenarios.

A huge thank you to the HKU Technology Commercialization Society (TCS) for organizing such a practical and impactful series for emerging innovators!

Learn more about the programme: https://tec.hku.hk/innovation-week-2026/programmes/tcs-pioneer-series-session-1-patents-that-matter-identifying-and-avoiding-common-pitfalls/

我們過去活動

Recommended Insights

Everything you need to know about Patent Term Adjustment (PTA) in China

2024年5月7日
We previously discussed patent term compensation for patent office delay (‘Patent Term Adjustment’ or ‘PTA’) when such new system was introduced in the Fourth Amendment of the Chinese Patent Law (2020), as well as in the different versions of the Draft Examination Guidelines released in 2021 and 2022. In this article, we consolidate everything you need to […]
CN1982128B Figure

2019 CHINA TOP 10 IP CASE: VALEO V. LUCAS, FUKE, & CHEN

2020年6月8日
Every year in the spring The Supreme People’s Court of PRC announces its “Top 10 Intellectual Property (IP) cases” and “50 typical IP cases in Chinese courts” of the year. Although not having precedential weight, these cases serve as a reference and guide people's courts at all levels regarding their intellectual property trials. It’s always […]

First ever Invalidation decision on an RNAi Invention patent in China

2023年12月4日
Decision on Examination of Request for Invalidation (No. 58530) In one of China’s Top 10 Patent Re-examination / Invalidation cases of 2022, an invalidation decision on a patent claiming Hepatitis B Virus (HBV) RNAi compositions (No. 58530) by the Patent Re-examination Board (the “Board”) sheds light on the standard for post filing data for rejections […]

NMPA's Releases Draft Measures for Data Protection (Data Exclusivity)

2025年9月4日
In March 2025, China's National Medical Products Administration (NMPA) released yet another set of draft implementation measures on data protection.1 Key highlights of these new measures include the following: A Bit of History China's journey toward a comprehensive pharmaceutical data protection framework has been ongoing for over two decades, a roller coaster ride from its […]
Top crossarrow-right